What Oxford Pharmagenesis does

Oxford PharmaGenesis is an independent, global HealthScience communications consultancy founded in 1998 and headquartered near Oxford, UK. The company provides strategic consultancy across medical communications, medical affairs, market access and value demonstration, health economics and outcomes research (HEOR), real-world evidence, publications planning, patient engagement, policy, and AI/data science, serving pharmaceutical companies, biotechnology firms, healthcare payers and HTA bodies, and patient advocacy organisations. Its service portfolio spans nine specialisations (Medical Affairs, Commercial and Marketing, Value Demonstration, Real-world Evidence, Rare Diseases, Patient Engagement, Policy, AI and Data Science, and QRdb) and is delivered by more than 500 employees across offices in the UK (Oxford HQ, London, Cardiff, Cambridge), the United States (Wilmington, DE), and Australia (Melbourne).

The firm's core technology is its proprietary "HealthScience" methodology, which integrates clinical and scientific dimensions with economic, social, behavioural, and political perspectives to determine the value of new medicines. It offers AI-powered systematic literature review services using third-party models (Elicit AI, GPT-4) with published accuracy of 78-95% under expert prompting, and operates QRdb, a registered integrated poster-hosting solution. The company also coordinates the OpenPharma initiative for evidence transparency and has partnered with OriginTrail (Trace Labs) on a verifiable global medical knowledge infrastructure. Underlying technical components include Boolean search workflows, AI-assisted screening and data extraction pipelines, and structured data extraction for cost, humanistic, and study-design parameters.

Oxford PharmaGenesis generates revenue through project-based professional services fees negotiated on a scope, complexity, and timeline basis with multi-year enterprise engagements. Its go-to-market is primarily direct enterprise field sales targeting pharmaceutical and biotech leadership, supplemented by industry event sponsorship (MAPA-MAPS, ISPOR, ISMPP), thought-leadership publishing, ESG and gender pay gap disclosures, and OpenPharma community engagement. FY2025 revenue was £50m (+14% YoY) with operating profit of £11.2m (+65% YoY); the firm is founder-led, privately held with no disclosed external investment, and recognised by the King's Award for Enterprise (2023), four consecutive years on the MM+M Agency 100, and multiple sustainability and security certifications (Cyber Essentials Plus, EcoVadis, ISO 14001, CDP A grade).

Name

Oxford Pharmagenesis

Legal name

Oxford PharmaGenesis Ltd

Website

https://pharmagenesis.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

Oxford PharmaGenesis is an independent, global HealthScience communications consultancy founded in 1998 that provides strategic medical communications, medical affairs, HEOR, real-world evidence, patient engagement, and AI-powered evidence synthesis services to pharmaceutical, biotech, and healthcare organisations across the UK, US, and Asia-Pacific.

Ownership category

akta.pro rank

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Healthcare Communications Consulting: Oxford PharmaGenesis operates as a healthcare communications consultancy providing strategic consultancy in medical communications, medical affairs, market access, value demonstration, HEOR, publications, patient engagement, and AI/data science services. Revenue is generated through professional services fees for project-based consulting engagements with pharmaceutical and healthcare clients.
2. Medical Affairs Services: Services include publications planning, real-world evidence studies, health economics and outcomes research (HEOR), market access strategy, and patient engagement programs delivered to pharmaceutical and biotech clients.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Oxford PharmaGenesis provides strategic consultancy services in medical communications, medical affairs, market access and value demonstration, health economics and outcomes research (HEOR), real-world evidence, publications planning, patient engagement, policy, and AI/data science to pharmaceutical, biotechnology, and healthcare clients worldwide. Engagements are delivered as project-based consulting work, supplemented by a proprietary AI-Powered Systematic Literature Review service and the QRdb integrated poster-hosting platform.

Product overview

Oxford PharmaGenesis is an independent, global HealthScience communications consultancy offering a portfolio of specialized service offerings rather than a unified software product. The core services include Medical Affairs, Commercial and Marketing, Value Demonstration, Real-world Evidence, Rare Diseases, Patient Engagement, Policy, and AI and Data Science. These services are delivered through specialized teams and practices. The company also offers two distinct branded offerings: QRdb, an integrated poster-hosting solution for conference presentations, and AI-Powered Systematic Literature Review services that combine AI tools (Elicit AI, GPT-4) with expert human oversight. The AI and Data Science practice supports evidence generation across all service areas using technologies like AI-assisted literature review and data analytics. The company also coordinates the Open Pharma initiative focused on research transparency.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Affairs Strategic consultancy services supporting medical affairs functions within pharmaceutical companies, including evidence generation, medical communications strategy, and stakeholder engagement for HCPs and payers.
• Commercial and Marketing Healthcare communications services for commercial and marketing functions, helping pharmaceutical and biotech clients develop strategies for market engagement, brand messaging, and launch planning.
• Value Demonstration Services focused on demonstrating the value of healthcare interventions through health economics and outcomes research (HEOR), payer communications, and market access support for pharmaceutical and biotech clients.
• Real-world Evidence Generation and communication of real-world evidence (RWE) studies to support clinical decision-making, health technology assessment, and market access for pharmaceutical and biotech clients.
• Rare Diseases Specialized communications consultancy for rare and orphan diseases, addressing unique challenges in patient engagement, evidence generation, and market access for underserved populations.
• Patient Engagement Services integrating patient perspectives into research design, funding decisions, and communications, including patient experience mapping and involvement programmes for pharmaceutical clients and patient advocacy organizations.
• Policy Health policy consultancy services including development of policy recommendations, advocacy communications, and engagement with policymakers and healthcare stakeholders for clients in the healthcare sector.
• AI and Data Science Artificial intelligence and data science services including AI-powered systematic literature reviews, informatics solutions, and implementation of new technologies for evidence synthesis supporting pharmaceutical clients.
• AI-Powered Systematic Literature Review (SLR) AI-enhanced systematic literature review services using tools such as Elicit AI and GPT-4 for data extraction, title/abstract screening, and study prioritization, combining AI with scientific rigour and human expert oversight for evidence synthesis.
• QRdb Proprietary integrated poster-hosting platform that provides hosting, management, and distribution of conference posters, enabling easy sharing and accessibility of research presentations for clients and conference attendees.

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, minor and flagship.

• OriginTrail (Trace Labs)coreStrategic or Co-development Partner · 3 September 2025Partnership with Trace Labs, core developers of OriginTrail, on a groundbreaking initiative to globally connect and verify medical knowledge. Aims to address fragmented clinical trial information and improve connectivity for medical research and patient care.
• Medical Affairs Professional Society (MAPS)coreStrategic or Co-development Partner · 26 January 2024Oxford PharmaGenesis Communications Director Gary Male joined the MAPS Evidence Generation Focus Area Working Group to help educate Medical Affairs professionals about evidence generation specialty area.
• LifeArccoreStrategic or Co-development Partner · 1 January 2024Established the MND Insights Group in 2024 to integrate lived experience of motor neuron disease into research funding and design decisions. The group convenes patients and bereaved caregivers to guide patient involvement practices for progressive, life-shortening conditions.
• Oxfordshire Community Foundation (OCF)minorStrategic or Co-development Partner · 28 November 2023Joined Oxfordshire Collective Business Fund, contributing £2000+ annually to support local charitable organizations and disadvantaged communities in Oxfordshire.
• Medical Affairs Professionals of Australasia (MAPA)coreChannel Partner/ Reseller/ Distributor · 8 November 2023Joint summit sponsorship and exhibitor presence at MAPA-MAPS Medical Affairs Summit in Sydney, Australia. Oxford PharmaGenesis was sponsor for the second consecutive year with team attendance including COO Richard White.
• Healthcare Information For All (HIFA) / World Health Organization (WHO)flagshipStrategic or Co-development Partner · 1 August 2023Platinum sponsor of global HIFA-WHO consultation to accelerate progress towards universal access to reliable healthcare information. Collaboration aims to demonstrate public support and inform WHO action on healthcare information accessibility.
• Oxford Health Policy ForumcoreStrategic or Co-development Partner · 1 January 2015Long-standing partnership on MS Brain Health initiative developing policy recommendations and educational resources for people with multiple sclerosis. Initiative gained endorsement from 50+ organizations and has 450 champions across 65+ countries.
• MS AustraliacoreStrategic or Co-development Partner · 1 January 2015Partnership with MS Australia to implement MS Brain Health recommendations and improve MS care in Australia. MS Australia has integrated recommendations into all its activities and championed the initiative nationally.

Scale indicators5 records

Recent moves2 records

Expansion highlights6 records

Direct peers

• CMI Media Group: Healthcare media and communications agency serving pharmaceutical clients with strategy, media planning, and creative services. Competes with Oxford PharmaGenesis for pharma marketing and communications engagements, particularly in the US market.
• MedThink Communications: Healthcare communications agency providing medical communications, digital strategy, and patient engagement services to pharmaceutical clients. Mid-sized direct peer with similar service offerings to Oxford PharmaGenesis.
• Precision Medicine Group: Specialized services company supporting pharma/biotech with medical communications, HEOR, market access, and commercial services. Directly comparable business model serving overlapping pharmaceutical client base.
• Avalere Health: Healthcare strategic advisory firm providing evidence, access, and policy services to pharmaceutical and healthcare organizations. Comparable to Oxford PharmaGenesis in HEOR, market access, and policy-focused consulting offerings.
• Fishawack Health: Global medical communications and healthcare marketing agency offering medical affairs, publications, and HEOR services to pharmaceutical clients. Directly comparable to Oxford PharmaGenesis in service portfolio and target customers, with similar global footprint.
• Ashfield MedComms (Inizio): Medical communications agency within Inizio group providing medical affairs, publications, and healthcare communications services. Directly competes for the same pharmaceutical and biotech client engagements as Oxford PharmaGenesis.

Broad incumbents

• McCann Health: Global healthcare advertising and communications network within McCann Worldgroup. Overlaps with Oxford PharmaGenesis on healthcare communications and creative services, but operates as part of a much larger advertising holding company with broader marketing capabilities.
• Syneos Health Communications: Large CRO with dedicated medical communications arm offering publications, medical affairs, and HEOR services to pharma clients. Broader portfolio including clinical development services positions it as a larger incumbent with overlapping medical communications offerings.
• Evidera (Thermo Fisher PPD): HEOR, RWE, and market access consulting firm owned by Thermo Fisher Scientific. Overlaps with Oxford PharmaGenesis' Value Demonstration and Real-world Evidence service lines, but as part of a much larger parent organization with broader clinical research capabilities.
• Huntsworth (now part of TPG Inc.): Healthcare and communications group including medical communications agencies. Historically competed with Oxford PharmaGenesis in medical communications space, now part of TPG's healthcare-focused portfolio.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/OxPharmaGenesis
• YouTubeyoutube.com/channel/UCfAIliulif67NRiemIEDB-w
• LinkedInlinkedin.com/company/oxford-pharmagenesis

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Pharmagenesis